The role of real-world evidence (RWE) in regulatory, drug development, and clinical decision-making is rapidly expanding. The recent release of FDA’s real-world evidence program framework [December 2018] for evaluating the potential use of RWE in regulatory settings underscores the growing importance of RWE in research. Therefore, clinical trial and drug development professionals need to understand the sources of real-world data (RWD), potential uses of RWE, as well as the limitations and strengths of each approach. This webinar will describe the current state of RWE science and provide context for the regulatory and research implications of RWD and RWE.
Senior Medical Director
Senior Director, Quality & Regulatory Solutions
The content of the regulatory-grade RWE webinar applies to all researchers and staff involved with design, conduct, coordination, monitoring, and interpretation of clinical research. For example, clinical trial sites (institutions as well as unaffiliated sites), sponsors, regulatory groups, CROs, and other research organizations. This topic is of special interest to regulatory stakeholders.
The presentation may qualify for continuing education credits; check with your certifying organization(s) for more information.
After completing this webinar in its entirety, you will receive a certificate of attendance. This certificate will include your full name, and it will be emailed to you at the end of the webinar. Please note that if your organization has other staff members who wish to get a certificate of attendance, each person must register, watch the webinar in its entirety, and take the survey at the end. Visit our Webinar Help page for more information on certificates of attendance.